Serpil Tekoglu

Serpil Tekoglu is a Researcher at the Institute of Physical Chemistry, Johannes Kepler University Linz (JKU), specializing in sustainable bioelectronic materials. Her work bridges chemistry, materials science, and medical technology through development of biodegradable conductive polymers and natural biopolymer-based devices.

Her research focuses on natural biopolymers for bioelectronics, particularly algal polysaccharides (sacran), DNA-based conductors, and ε-poly-L-lysine copolymers. Key interests include achieving long-term biocompatibility in implantable devices, ultrathin flexible electronics for medical applications, and eco-friendly manufacturing processes. She investigates material degradation pathways, stability mechanisms, and sustainable alternatives to conventional electronics.

Analysis of her 2025 publications reveals a cohesive trajectory toward medical-grade biodegradable electronics. Her work consistently integrates natural polymers with conductive elements to solve core challenges in bioelectronic interfaces - particularly stability in physiological environments and environmental sustainability. This spans from fundamental material synthesis (e.g., enzyme entrapment techniques) to functional device fabrication (OECTs, solar cells), with strong emphasis on real-world medical applications like biodegradable rapid tests.

Dr. Tekoglu leads the federally funded project BIOCOM - Biocompatible conductive polymers for medical applications (2023-2025) and actively mentors junior researchers. Her 20+ conference activities since 2024 include 6 invited talks at institutions like Universität Ferrara, demonstrating international recognition of her work on sustainable bioelectronics.

She operates within JKU's multidisciplinary bioelectronics team, collaborating with physicists, chemists, and medical researchers. Current efforts focus on translating lab innovations to clinical applications, particularly biodegradable diagnostic devices highlighted in Austrian media coverage (May 2025) regarding "the future of rapid tests".